These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36645166)

  • 21. Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema.
    Gjorup CA; Groenvold M; Hendel HW; Dahlstroem K; Drzewiecki KT; Klausen TW; Hölmich LR
    Eur J Cancer; 2017 Nov; 85():122-132. PubMed ID: 28918186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant nivolumab therapy may not improve disease-free survival in resected acral lentiginous melanoma patients: A retrospective case series.
    Maeda T; Yanagi T; Miyamoto K; Tokuchi K; Kitamura S; Ujiie H
    Dermatol Ther; 2022 Nov; 35(11):e15817. PubMed ID: 36093750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
    Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
    Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life, fatigue, and depression under low-dose IFN-α therapy in melanoma patients.
    Reuter K; Albrecht K; Seelig H; Meiss F; Mauch C; Kreuzberg N; Nashan D
    J Immunother; 2014; 37(9):461-7. PubMed ID: 25304729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
    O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
    Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
    Mandala M; Larkin J; Ascierto PA; Del Vecchio M; Gogas H; Cowey CL; Arance A; Dalle S; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Lutzky J; De La Cruz-Merino L; Atkinson V; Arenberger P; Hill A; Fecher L; Millward M; Khushalani NI; de Pril V; Lobo M; Weber J
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial.
    Fraterman I; Wollersheim BM; Tibollo V; Glaser SLC; Medlock S; Cornet R; Gabetta M; Gisko V; Barkan E; di Flora N; Glasspool D; Kogan A; Lanzola G; Leizer R; Mallo H; Ottaviano M; Peleg M; van de Poll-Franse LV; Veggiotti N; Śniatała K; Wilk S; Parimbelli E; Quaglini S; Rizzo M; Locati LD; Boekhout A; Sacchi L; Wilgenhof S
    JMIR Res Protoc; 2023 Oct; 12():e49252. PubMed ID: 37819691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients.
    Ellebaek E; Svane IM; Schmidt H; Haslund CA; Donia M; Hoejberg L; Ruhlmann C; Guldbrandt LM; Køhler UH; Bastholt L
    Cancer Epidemiol; 2021 Aug; 73():101943. PubMed ID: 33962356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immune checkpoint inhibitors for treatment of advanced stage melanoma].
    Lupu J; Herrscher H; Robert C
    Rev Prat; 2020 May; 70(5):471-474. PubMed ID: 33058629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Which adjuvant treatment for patients with BRAF
    Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P
    Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
    Hyatt A; Gough K; Murnane A; Au-Yeung G; Dawson T; Pearson E; Dhillon H; Sandhu S; Williams N; Paton E; Billett A; Traill A; Andersen H; Beedle V; Milne D
    BMJ Open; 2020 Feb; 10(2):e036059. PubMed ID: 32114479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
    Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
    Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?
    Rhodin KE; Jung SH; Elleson K; DePalo D; Straker R; McKinley S; Beekman K; Parker L; Chen S; Iyer MK; Salama AKS; Bartlett E; Karakousis G; Zager JS; Tyler DS; Beasley GM
    Ann Surg Oncol; 2023 Oct; 30(11):6340-6352. PubMed ID: 37481487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of adjuvant immune checkpoint inhibitor therapy in melanoma: a retrospective study.
    Sarah F; Margot R; Valerie B; Alexander D; Lieve B; Sylvie R; Celine J; Michael S
    Acta Clin Belg; 2024 Sep; ():1-9. PubMed ID: 39268967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
    Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
    Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
    Khattak MA; Luke JJ; Long GV; Ascierto PA; Rutkowski P; Schadendorf D; Robert C; Grob JJ; de la Cruz Merino L; Del Vecchio M; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Carlino MS; Mohr P; De Galitiis F; Ross MI; Eroglu Z; Chen K; Jiang R; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Kirkwood JM
    Eur J Cancer; 2022 Nov; 176():207-217. PubMed ID: 36202690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
    Herrscher H; Robert C
    Curr Opin Oncol; 2020 Mar; 32(2):106-113. PubMed ID: 31876547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.
    Bloemendal M; Rietveld MJA; van Willigen WW; Gerritsen WR; Figdor CG; Bonenkamp JJ; Westdorp H; Boudewijns S; Koornstra RHT; Adang EMM; Schreibelt G; Ottevanger PB; de Vries IJM; Bol KF
    Clin Transl Oncol; 2019 Jun; 21(6):774-780. PubMed ID: 30465182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.